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Abstract: Melatonin (N-acetyl-5-methoxy-tryptamine), a naturally occurring indole produced 
mainly by the pineal gland, is a well known antioxidant. Stroke (cerebral ischemia) is the 
second leading cause of death worldwide. To date, however, effective and safe treatment for 
stroke remains unavailable. Melatonin is both lipid- and water-soluble and readily crosses 
the blood–brain barrier (BBB). Increasing evidence has shown that, in animal stroke models, 
administering melatonin signiﬁ  cantly reduces infarct volume, edema, and oxidative damage 
and improves electrophysiological and behavioral performance. Here, we reviewed studies 
that assess effects of melatonin on cerebral ischemia in acute, sub-acute, and chronic stages. 
In addition to its potent antioxidant properties, melatonin exerts antiapoptotic, antiexcitotoxic, 
anti-inﬂ  ammatory effects and promotes mitochondrial functions in animals with cerebral 
ischemia. Given that melatonin shows almost no toxicity to humans and possesses multifac-
eted protective capacity against cerebral ischemia, it is valuable to consider using melatonin in 
clinical trials on patients suffering from stroke.
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Introduction
Stroke (hypoxia/ischemia or ischemia) is the second leading cause of death throughout 
the world. Focal cerebral ischemia is the major form of stroke and is usually caused 
by thromboembolic occlusion of supplying arteries. In contrast, global ischemia is 
often caused by cardiac arrest, massive hemorrhage, or carbon monoxide poisoning. In 
either circumstance, brain damage occurs when cerebral blood ﬂ  ow drops to 25% of its 
normal value.1,2 The longer duration of occlusion, the greater damage to the brain and 
such impairment is usually irreversible. However, limited therapeutic treatments are 
available clinically and these treatments are only applicable to highly selected groups. 
For example, tissue plasminogen activator (t-PA), which is the only US Food and Drug 
Administration (FDA)-approved drug for acute stroke treatment, and prourokinase 
used for thrombolysis and modiﬁ  ed viper venom used for deﬁ  brinogenation need to 
be applied to patients within three to six hours, and it has been noted that these agents 
increase incidence of intracerebral hemorrhage.3,4 Thus, there is an urgent need to have 
a safe and effective treatment for a larger group of stroke patients.
Reduced blood supply rapidly leads to metabolic failure in the recipient tissues, and 
such energy shortage directly causes imbalance of ionic gradients across membrane, 
accumulation of intracellular calcium and sodium ions and reduction of pH. Abnormal 
ion and pH gradients disrupt membrane transport, mitochondrial functions and 
protein production as well as activate Ca2+-dependent enzymatic reaction. As a result 
of respiratory chain failure, generation of excessive free radicals leads to membrane 
lipoperoxidation and damages cellular organelles and cytoskeleton. Pro-apoptotic 
events are initiated, such as activation of nuclear factor κB (NFκB)- and p53-dependent 
pathways, decreased Bcl-2 to Bax ratio, release of cytochrome c oxidase from mito-
chondria and caspase activation, and eventually activate DNA-breaking enzymes Neuropsychiatric Disease and Treatment 2009:5 158
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and the energy-consuming DNA repair enzymes resulting 
in DNA breakdown and cell death.5,6 Massive cell death 
in the brain harms neural network and ultimately impairs 
neurological functions.
Primary therapeutic strategy in treating cerebral ischemia 
is to restore blood ﬂ  ow, so that ischemic tissues can be reper-
fused (or reoxygenated) in the shortest time possible (ideally 
within minutes) in order to preserve neural tissues, which 
is also in favor of later functional recovery and survival of 
individuals. Secondary approach is to ameliorate pathophysi-
ological consequences of stroke, including excitotoxicity, 
apoptosis, inflammation, penumbral depolarization and 
diaschisis, caused by free radicals generated during hypoxia/
ischemia and reperfusion. For the former purpose, t-PA 
and other thrombolytic agents are applied. For the latter, 
melatonin would be an ideal therapeutic agent since it is a 
naturally occurring antioxidant, has a known safety proﬁ  le 
being virtually nontoxic to humans,7 and readily crosses 
the blood–brain barrier (BBB) when administrated through 
peripheral routes.
Melatonin (N-acetyl-5-methoxy-tryptamine) is an 
indole endogenously produced by several mammalian 
organs, including the pineal gland, retina, and gastroin-
testinal tract.1 In addition to other endogenously produced 
molecules which showed beneficial effects in animal 
models of stroke, including estrogen,8 erythropoietin9,10,11 
cannabinoids,12,13 melatonin is a potent free radical scaven-
ger and an antioxidant. It can directly detoxify both reactive 
oxygen, including hydroxyl radical (•OH), H2O2 and singlet 
oxygen (1O2), and nitrogen species, such as nitric oxide 
(NO•), peroxynitrite anion (ONOO-), and peroxynitrous 
acid (ONOOH or its activated form, ONOOH•).14 Mela-
tonin is also an indirect antioxidant as it can regulate the 
activities of enzymes which promote overall antioxidative 
defense systems in an organism, including glutathione 
peroxidase (GSH-Px), glutathione reductase (GSH-Rd), 
superoxide dimutase (SOD), and glucose-6-phosphate 
dehydrogenase (G-6-PD).15 In addition, metabolites formed 
from interaction of melatonin with free radicals, including 
N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and 
N1-acetyl-5-methoxykynuramine (AMK), are also efﬁ  cient 
radical scavengers.16–18
Although a considerable number of agents showed 
neuroprotective effects in animal stroke studies, more 
than 100 neuroprotectants have failed clinical trials of 
acute ischemic stroke (AIS). Attention has been drawn 
recently to modify criteria for evaluating preclinical meth-
ods and data due to the latest failed clinical trials on a 
free radical-trapping agent, NXY-059, in AIS.19 Analyses 
indicated that NXY-059 lacks rigorous testing paradigms in 
animal models and does not have replicated evidence on its 
protective effects in extended time window.20–22 Suggestions 
were made that future stroke study needs to be made on more 
clinical relevant animal models, such as those with other 
co-morbidity (diabetes, hypertension, etc.). Since stroke 
is mainly a cardiovascular disease affecting neurological 
functions, research on the neurovascular system, including 
neurons, supplying microvessels, endothelium, and glial 
cells (astrocytes, microglia, and pericytes) will be of great 
value. Moreover, it is clinically relevant to evaluate effects 
of a neuroprotectant on the non-ischemic hemisphere and 
the penumbral regions in the ischemic hemisphere as well 
as to assess whether it ameliorates complications associated 
with stroke, including inﬂ  ammation and electrophysiological 
and behavioral deﬁ  cits. This paper aims to analyze available 
results on the effects of melatonin in animal stroke models 
at different pathophysiological stages.
Effects of melatonin in acute stroke
In accordance with the common clinical scenario of stroke, 
rodent models of focal cerebral ischemia with middle cerebral 
artery (MCA) occlusion have been widely studied in the 
laboratory. Temporary occlusion of MCA is performed for 
60–90 minutes, and melatonin is administered either before 
ischemia or shortly after reperfusion. Several physiological 
parameters, including pH, pCO2, pO2, core temperature and 
blood pressure, are monitored during the course of study and 
are found unchanged upon administration of melatonin.23,24 
Abundant literature demonstrated that administering 
melatonin signiﬁ  cantly reduces brain infarction, neurological 
deﬁ  cits, and a number of outcome measurement, which has 
been systemically analyzed and the effect size of melatonin 
is reported around 0.5.25
The protective effects of melatonin in acute stroke 
(within two days from the onset of vessel occlusion) 
mainly derives from that melatonin is a direct and indirect 
antioxidant and that it promotes mitochondrial functions. 
Antioxidant actions of melatonin include scavenging of 
free radicals and increasing activity of antioxidant enzymes 
as described above. Moreover, melatonin suppresses nitric 
oxide production by reducing nNOS synthesis in neurons 
in a calmodulin-dependent pathway26 and abolishing iNOS 
expression in macrophages through a NFκB-mediated 
mechanism.27 In addition, melatonin stimulates the activity of 
NADH-coenzyme Q reductase (Complex I) and cytocrhome c 
oxidase (Complex IV) in the electron transport chain (ETC) Neuropsychiatric Disease and Treatment 2009:5 159
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of mitochondria and consequently reduces electron leakage 
and free radical production and maintains normal adenosine 
triphosphate (ATP) production.28,29 This suggests that 
administering melatonin in stroke could counteract energy 
shortage to maintain normal cellular function and to decrease 
brain damage. The ability of melatonin to reduce oxidative 
damage caused by ischemia has been reported in other organs, 
such as heart,30 liver,31,32 and kidney.33
Melatonin decreases excitotoxicity and cerebral inﬁ  ltration 
of immune cells after cerebral hypoxia/ischemia. Since the 
pineal gland is the major source of melatonin in the body, 
pinealectomy was performed on animals to study the effects 
of endogenous melatonin on cerebral injury. Pinealectomized 
rats exhibit greater neuronal degeneration and DNA damage 
in the hippocampus following kainate injection, suggesting 
that endogenous production of melatonin protects the brain 
against excitotoxic injury.34 Consistent with previous studies 
with exogenous source of melatonin, pinealectomized 
rats show larger cortical infarction four or six hours after 
middle cerebral artery occlusion (MCAO) compared with 
control animals. Moreover, melatonin is capable of reducing 
cerebral inﬂ  ammation after stroke. Administering melatonin 
at the onset of reperfusion decreases microglial/macrophage 
activation and reduces immune cell inﬁ  ltration to the ischemic 
hemisphere without changing the cellular immune response 
in the blood stream at two days post-MCAO.35 Although 
such effect could be, at least in part, a result of decreased 
infarction and other brain damage after melatonin treatment, 
it has been shown that in an inﬂ  ammatory rat model of 
colitis administering melatonin suppresses the mRNA and 
protein expression of tumor necrosis factor-α (TNF-α) 
and intercellular adhesion molecule-1 (ICAM-1) in colon 
tissues.36 Both membrane and nuclear receptors for melatonin 
have been identiﬁ  ed in peripheral blood mononuclear cells, 
and melatonin stimulation modulates their differentiation, 
proliferation, and cytokine production,37 indicating a direct 
role of melatonin in controlling immune systems.
Melatonin reduces apoptosis after stroke. Administering 
melatonin prior to MCAO or at the onset of reperfusion 
restores the injury-induced reduction in phosphorylated AKT 
(p-AKT), p-Bad and Bcl-XL levels and the binding of p-Bad 
and 14-3-3 as well as decreases caspase-3 activation.38,39 
Treatment of melatonin also suppresses the immunoreactivity 
of cytosolic cytochrome c oxdiase in the ischemic cortex 
four and 24 hours after MCAO.40 To investigate whether 
melatonin directly inhibits neuronal apoptosis after hypoxia/
ischemia, mouse striatal neurons are cultured and subjected 
to oxygen and glucose deprivation (OGD). Results showed 
that melatonin prevents the OGD-induced mitochondrial 
membrane depolarization and abolishes the NMDA-induced 
increase in the intracellular Ca2+ levels. It suggests that the 
antiapoptotic effect of melatonin lies in its inhibition on 
mitochondrial permeability. Interestingly, as astrocytes have 
an important role in maintaining brain homeostasis, recent 
studies demonstrated that melatonin can also reduce gluta-
mate- or H2O2-induced apoptosis in C6 astroglial cells.41
Melatonin ameliorates brain damage caused by the clinically 
used thrombolytic agent, t-PA, in animal stroke models. In 
addition to the widely-studied intraluminal occlusion model 
of cerebral ischemia, a laser beam-induced occlusion 
in the cerebral artery has also been invented. In contrast to 
the use of an Arc beam (which induces ﬁ  brin predominantly), 
the laser beam generates embolism which is similar to the 
composition of thrombus in humans,42–44 making it an ideal 
model for human stroke. Studies showed that administering 
melatonin in combination with t-PA at the onset (MCAO) or 
six hours after reperfusion (laser-beam induced occlusion) 
decreases t-PA induced iNOS expression and hemorrhagic 
formation as well as restores p-AKT levels.45
Cumulatively, in an acute stage of cerebral hypoxia/isch-
emia melatonin shows a capacity to reduce brain damage 
by 1) reducing oxidative stress, 2) promoting mitochondrial 
functions, 3) decreasing excitotoxicity, 4) suppressing 
inﬂ  ammation and 5) diminishing apoptosis.
Effects of melatonin on stroke 
in sub-acute stage
Animal studies have been performed to assess the effects 
of melatonin on stroke in a sub-acute stage (3–14 days). 
Melatonin-treated animals exhibit improved electrophysi-
ological response compared to vehicle-treated controls 
at three days post-MCAO.24 The somatosensory evoked 
potentials (SSEPs) are recorded in the left and right primary 
somatosensory cortex (SI) by stimulating its respective 
contralateral fore- or hindpaw. The waveforms of the ﬁ  rst 
positive (P1) and the ﬁ  rst negative (N1) peaks are used 
for latency and amplitude measurements. Animals with 
stroke have severely depressant P1/N1 amplitude in the 
ischemic forepaw and hindpaw cortical ﬁ  elds but leaving 
the latency unchanged. Transcallosal diaschisis is observed 
in the contralateral hindpaw, but not forepaw, cortical 
ﬁ  eld where P1/N1 amplitude is decreased and P1 latency 
is increased when compared to the pre-ischemic baseline. 
Administering melatonin reverses the depressant SSEPs in 
not only the ischemic forepaw and hindpaw cortical ﬁ  elds 
but also the contralateral hindpaw cortical ﬁ  eld. Consistently, Neuropsychiatric Disease and Treatment 2009:5 160
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melatonin-treated animals show improved motor and sensory 
behavioral scores than vehicle-treated controls.
Similar to brain ischemia, in the spinal cord-injured rats 
administering melatonin immediately after trauma improves 
motor and sensory evoked potentials as well as behavioral 
performance (motor function score and inclined plane test) 
10 days after injury.46 Biochemical analyses showed that 
melatonin treatment reduces lipid peroxidation in acute 
(4 and 24 hour) and sub-acute phases (day 10), compared 
to untreated injured controls. In summary, these studies 
show that the neuroprotective effects of melatonin remain 
signiﬁ  cant in a sub-acute phase and that administrating 
melatonin can effectively prevent electrophysiological and 
behavioral deﬁ  cits caused by cerebral hypoxia/ischemia and 
spinal cord injury.
Long-term effects of melatonin 
in stroke
The effects of melatonin after long-term recovery (more than 
one month) have just been reported lately. Melatonin shows 
beneﬁ  cial effects 120 days after global ischemia.47 Global 
ischemia was performed for 15 minutes in rats and melatonin 
was intravenously administered 30 minutes after the end of 
ischemia and continued for six hours. Place learning (Morris 
water maze) and working memory (eight-arm Olton radial 
maze) was assessed 90 days after ischemia and the pyramidal 
neurons in cornus Ammoni (CA) region and layers III and V 
of the medial prefrontal cortex was examined at 120 days 
post-injury (at the end of behavioral testing). Global ischemia 
causes a signiﬁ  cant delay in acquisition of working memory 
and impairs place learning as well as reduces pyramidal 
neurons in the Ammon’s horn. As expected, melatonin-treated 
animals performed signiﬁ  cantly better than vehicle-treated 
controls and similarly to the sham group. In addition, mela-
tonin prevented the ischemia-induced pyramidal neuron loss 
in the CA regions when compared to vehicle-treated controls, 
but the remaining neurons in melatonin-treated rats displayed 
less ramiﬁ  ed dendrites than intact controls. In spine struc-
tures, melatonin-treated animals showed lower density of 
spines, mainly composed of mushroom spines, than intact 
controls. These results suggest that melatonin can counter-
act the pathophysiological damage caused by ischemia in a 
long run by preserving neuronal cells and certain degree of 
the cytoarchitecture of dendrites. Interestingly, it has been 
shown that melatonin activates Ca2+-dependent alpha iso-
form of protein kinase C (PKC) and binds to Ca2+-activated 
calmodulin to cause microtubule enlargement and neurite 
outgrowth, and such effect has been implicated in melatonin’s 
preservation of neuronal cytoskeletal organization following 
brain damage.48,49
Furthermore, the role of melatonin in neurogensis has 
been studied by several different groups but different results 
were shown. Acute intraperitoneal (ip) injection or chronic 
treatment of melatonin (in drinking water) was administered 
on gerbils and the immunoreactivity of doublecortin (Dcx), 
a marker for newly generated neurons, was examined in the 
hippocampus 20 weeks after cerebral ischemia.50 Results 
showed that either acute or chronic treatment of melatonin 
failed to further increase the number of Dcx-positive cells 
in CA1 regions and decreased the Dcx-positive cells in the 
dentate gyrus. In the same line, in neural stem cells (NSC) 
derived from mouse embryo striatum melatonin at pharma-
cological concentrations (1–100 micromolar) suppressed 
epidermal growth factor (EGF)-induced NSC proliferation 
and reduced 1% fetal bovine serum (FBS)-containing 
medium-induced neuronal differentiation without affecting 
astroglial differentiation.51 In direct contrast, Kilic and 
colleagues revealed that delayed (one day after MCAO) 
and continuous treatment of melatonin (in drinking water) 
for 29 days increased the number of Dcx-positive cells in 
the subventricular zone (SVZ) in mice.52 It is intriguing 
whether following cerebral hypoxia/ischemia SVZ and 
hippocampal stem cells respond differently to chronic 
treatment of melatonin and whether the difference is a 
result of a modiﬁ  ed stem cell niche after long exposure to 
melatonin. Further studies are warranted. In the notion that 
melatonin has anti-inﬂ  ammatory properties, administering 
indomethacin, a nonsteroidal anti-inﬂ  ammatory drug, starting 
three days before MCAO and continued for 14 or 28 days 
after ischemia reduces microglial/macrophage activation 
and increases proliferating cells of all lineage in the cortex 
and striatum after cerebral hypoxia/ischemia.53 It supports a 
neurogenic hypothesis of melatonin after stroke and suggests 
a mechanism in which melatonin promotes neurogenesis by 
suppressing inﬂ  ammation, and more extensive studies are 
required to examine these points.
Studies from our lab showed that after MCAO the level 
of synaptic proteins is signiﬁ  cantly higher in the melatonin-
treated rats compared to vehicle-treated controls; the dendrite 
density of pyramidal neurons in the ischemic core, penumbra 
and forelimb and hindlimb somatosensory cortical areas is 
higher in the melatonin-treated rats than vehicle-treated con-
trols at seven days post-injury (unpublished data). Consistent 
with the results on melatonin-treated rats three days after 
MCAO, melatonin improved animals’ electrophysiological 
response at 28 days post-injury (unpublished results). Neuropsychiatric Disease and Treatment 2009:5 161
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Overall, melatonin treatment shows long-term beneﬁ  ts in 
experimental stroke studies, and data up till today suggest 
that the effect is a result of better preserved brain tissues in 
the acute stage.
Concluding remarks
In addition to its initial protective effects as a free radical 
scavenger and antioxidant, abundant studies showed that 
melatonin has multifaceted properties acting against cerebral 
hypoxia/ischemia and its protection could be long-lasting 
over months. The outcome measurements in these animal 
studies, including infarction volume, edema, BBB integrity, 
electrophysiology, and motor and sensory behaviors, are 
useful translational parameters and applicable to clinical 
assessments for the prognosis of stroke patients. Further 
studies are recommended to evaluate effects of melatonin on 
stroke animals with other co-morbidity since the physiologi-
cal background of animals might affect the effectiveness of a 
treatment and determines whether clinical trials will succeed. 
Interestingly, gender difference has also been noted in our 
studies where female animals require lower dose of melatonin 
to confer neuroprotection after MCAO compared to male 
counterparts (unpublished observation). It has been shown 
that estradiol signiﬁ  cantly reduces damage caused by cerebral 
ischemia.54,55 It is possible that estrogen and melatonin have 
synergistic effects and play important roles in determining the 
severity of cerebral ischemia. This hypothesis requires further 
investigation. Moreover, neurogenic effects of melatonin 
remain an important ﬁ  eld to explore since it provides impor-
tant information whether long-term use of melatonin will be 
helpful for stroke patients.
As melatonin has long been used for ameliorating sleep 
disturbance and shows no toxicity on humans, clinical 
trials assessing effects of melatonin on other neurological 
disorders, including amyotrophic lateral sclerosis (ALS) 
and Alzheimer’s disease, have been conducted. In a 
group of 31 patients with sporadic ALS, high-dose of 
melatonin (300 mg/day) given rectally was well tolerated 
up to two years of observation and it reduced the level of 
circulating serum protein carbonyls, which is indicative of 
oxidative stress.56 Another double-blind study was conducted 
on 20 patients with Alzheimer’s type of dementia where 
melatonin (3 mg) was given continuously for four weeks, 
and results showed that melatonin treatment improved sleep 
time and night activity as well as cognitive and noncognitive 
functions.57 Similar results were reported by a different group 
on a larger size of group (45 patients) with longer treatment 
paradigm (four month period with 6 mg/day).58 Data from 
these clinical trials suggest that administering melatonin is 
safe and improves neurological functions. In our perspec-
tive, administrating melatonin should be done in a timely 
manner as soon as cerebral ischemia occurs and ideally within 
three hours.59 With its potent antioxidant capacity and other 
anti-apoptosis and anti-inﬂ  ammatory effects, melatonin could 
be therapeutically useful in a clinical setting for patients 
suffering from cerebral ischemia.
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